Advertisement

Der Einsatz von Vasodilatatoren bei chronischer Herzinsuffizienz

  • W.-D. Bussmann
Part of the Handbuch der inneren Medizin book series (INNEREN, volume 9 / 4)

Zusammenfassung

Das chronisch insuffiziente Herz verfügt über spezielle Anpassungsmechanismen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ader R, Chatterjee K, Ports T, Hiramatsu B, Parmley WW (1979) Beneficial hemodynamic effects of angiotensin converting enzyme inhibitor in chronic refractory heart failure. Am J Cardiol 43:404 (Abstr)Google Scholar
  2. Ader R, Chatterjee K, Ports T, Brundage B, Hiramatsu B, Parmley WW (1980) Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation 61:931–937PubMedGoogle Scholar
  3. Ahlquist RP (1948) A study of the adrenergic receptors. Am J Physiol 153:586–600PubMedGoogle Scholar
  4. Amann FW, Bühler FR, Conen D, Brunner F, Ritz R, Speck B (1980) Captopril-associated agranulocytosis. Lancet 1:150PubMedGoogle Scholar
  5. Antonaccio MJ, Kerwin L (1981) Pre- and postjunctional inhibition of vascular sympathetic function by captopril in SHR. Hypertension [Suppl I] 3:54–62Google Scholar
  6. Arnold SB, Williams RL, Pots TA, Baughman RA, Benot LZ, Parmley WW, Chatterjee K (1979) Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Intern Med 91:345–349PubMedGoogle Scholar
  7. Aronow WS, Danahy DT (1978) Efficacy of trimazosin and prazosin therapy on cardiac and exercise performance in outpatients with chronic congestive heart failure. Am J Med 65:155–160PubMedGoogle Scholar
  8. Aronow WS, Lurie M, Turbow M, Whittaker K, Van Camp S, Hughes D (1979) Effect of prazosin vs placebo on chronic left ventricular heart failure. Circulation 59:344–350PubMedGoogle Scholar
  9. Awan NA, Mason DT (1981) Oral vasodilator therapy with prazosin in severe congestive heart failure. Am Heart J 101:695–700PubMedGoogle Scholar
  10. Awan NA, Miller RR, DeMaria AN, Maxwell KS, Neumann A, Mason DT (1977) Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Circulation 56:346–354PubMedGoogle Scholar
  11. Awan NA, Miller RR, Mason DT (1978a) Comparison of effects of nitroprusside and prazosin on left ventricular function and the peripheral circulation in chronic refractory congestive heart failure. Circulation 57:152–159Google Scholar
  12. Awan NA, Miller RR, Miller MP, Specht K, Vera Z, Mason DT (1978b) Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Am J Med 65:146–154Google Scholar
  13. Awan NA, Lee G, DeMaria AN, Mason DT (1981) Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. Am Heart J 101:541–547PubMedGoogle Scholar
  14. Awan NA, Amsterdam EA, Hermanovick J, Bommer WJ, Needham KE, Mason DT (1982) Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure. Am Heart J 103:474–479PubMedGoogle Scholar
  15. Becker HJ, Waiden B, Kaltenbach M (1976) Gibt es eine Tachyphylaxie bzw. Gewöhnung bei der Behandlung der Angina pectoris mit Nitrokörpern. Verh Dtsch Ges Inn Med 82:1208–1210Google Scholar
  16. Bertel O, Burkard F (1981) Langzeitresultate der Vasodilatator-Therapie mit Prazosin bei therapierefraktärer schwerer Herzinsuffizienz. Therapeut Umschau 38:45–48Google Scholar
  17. Blasini R, Froer KL, Blümel G, Rudolph W (1982) Wirkungsverlust von Isosorbiddinitrat bei Langzeitbehandlung der chronischen Herzinsuffizienz. Herz 7:250–258PubMedGoogle Scholar
  18. Bounhoure JP, Kayanakis JG, Fauvel JM, Puel J (1982) Beneficial effects of captopril in left ventricular failure in patients with myocardial infarction. Br J Clin Pharmacol [Suppl 2] 14:187S–191SGoogle Scholar
  19. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and betaadrenergic-receptor density in failing human hearts. N Engl J Med 307:205–211PubMedGoogle Scholar
  20. Burkard F, Bertel O (1983) Prazosin therapy in severe chronic congestive heart failure. In: Just H, Bussmann W-D (eds) Vasodilators in chronic heart failure. Springer, Berlin Heidelberg New York, pp 139–146Google Scholar
  21. Burrett JD, Eggena P, Krall JF, Sambhi MP (1981) A comparison of physical characteristics of active renin isolated from aorta, plasma and kidney of the rat. Clin Sci 61:671–678Google Scholar
  22. Bussmann W-D (1974) Kontraktilitätsreserve des linken Ventrikels unter körperlicher und pharmakologischer Belastung bei verschiedenen Herzerkrankungen. Habilitationsschrift, Universität FrankfurtGoogle Scholar
  23. Bussmann W-D (1983) Nitrates in chronic heart failure. In: Just H, Bussmann W-D (eds) Vasodilators in chronic heart failure. Springer, Berlin Heidelberg New York, pp 112–123Google Scholar
  24. Bussmann W-D, Schupp D (1978) Effect of sublingual nitroglycerin in emergency treatment of severe pulmonary edema. Am J Cardiol 41:931–936PubMedGoogle Scholar
  25. Bussmann W-D, Heeger J, Kaltenbach M (1977a) Kontraktilitäts- und Relaxationsreserve des linken Ventrikels. I. Normaler linker Ventrikel. Z Kardiol 66:690–695Google Scholar
  26. Bussmann W-D, Heeger J, Kaltenbach M (1977b) Kontraktilitäts- und Relaxationsreserve des linken Ventrikels. II. Patienten mit rheumatischen Vitien. Z Kardiol 66:696–705Google Scholar
  27. Bussmann W-D, Heeger J, Kaltenbach M (1978a) Kontraktilitäts- und Relaxationsreserve des linken Ventrikels. III. Patienten mit Myokardiopathie. Z Kardiol 67:18–27Google Scholar
  28. Bussmann W-D, Heeger J, Kaltenbach M (1978b) Kontraktilitäts- und Relaxationsreserve des linken Ventrikels. VI. Patienten mit koronarer Herzkrankheit. Z Kardiol 67:28–40Google Scholar
  29. Case DB, Atlas SA, Mouradian JA, Fishman RA, Sherman RL, Laragh JH (1980) Proteinuria during long-term captopril therapy. JAMA 244:346–349PubMedGoogle Scholar
  30. Chatterjee K, Parmley WW (1977) The role of vasodilator therapy in heart failure. Prog Cardiovasc Dis 19:301PubMedGoogle Scholar
  31. Chatterjee K, Parmley WW, Swan HJC, Berman G, Forrester J, Marcus HS (1973) Beneficial effects of vasodilator agents in severe mitral regurgitation due to dysfunction of subvalvar apparatus. Circulation 48:684–690PubMedGoogle Scholar
  32. Chatterjee K, Drew D, Parmley WW, Klausner SC, Polansky J, Zacherle B (1976a) Combination vasodilator therapy for severe chronic congestive heart failure. Ann Intern Med 85:467–470Google Scholar
  33. Chatterjee K, Parmley WW, Massie B, Greenberg B, Werner J, Klausner S, Norman A (1976b) Oral hydralazine therapy for chronic refractory heart failure. Circulation 54:879–883Google Scholar
  34. Chatterjee K, Brundage B, Parmley WW (1979) Oral hydralazine-pharmacology and clinical applications in chronic heart failure. In: Gould L, Reddy CVR (eds) Vasodilator therapy for cardiac disorders. Futura, Mount Kisco, New York, pp 179–208Google Scholar
  35. Chatterjee K, Ports T, Brundage B, Massie B, Holly AN, Parmley WW (1980) Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects. Ann Intern Med 92:600–604PubMedGoogle Scholar
  36. Chatterjee K, Rouleau J-L, Parmley WW (1982) Hemodynamic and myocardial metabolic effects of captopril in chronic heart failure. Br Heart J 47:233–238PubMedGoogle Scholar
  37. Chidsey CA, Kaiser GA, Sonnenblick EH, Spann JF, Braunwald E (1964) Cardiac norepi-nephrine stores in experimental heart failure in the dog. J Clin Invest 43:2386–2393PubMedGoogle Scholar
  38. Cogan J, Humphreys M, Carlson J, Rapaport E (1979) Afterload reduction increases renal blood flow and maintains glomerular filtration rate in patients with congestive heart failure. Clin Res 27:3A (Abstr)Google Scholar
  39. Cohn JN, Levine TB (1982) Angiotensin-converting enzyme inhibition in congestive heart failure: The concept. Am J Cardiol 49:1480–1483PubMedGoogle Scholar
  40. Colucci WS, Wynne J, Holman BL, Braunwald E (1980) Long-term therapy of heart failure with prazosin: a randomized double blind trial. Am J Cardiol 45:337–344PubMedGoogle Scholar
  41. Constantine JW, McShane WK, Scriabine A, Hess HJ (1973) Analysis of the hypotensive action of prazosin. In: Onesti G, Kim KE, Moyer JH (eds) Hypotension: Mechanisms and management. Grune & Stratton, New York, pp 429–444Google Scholar
  42. Creager MA, Halperin JL, Bernard DB, Faxon DP, Melidossian CD, Gavras H, Ryan TJ (1981) Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation 64:483–489PubMedGoogle Scholar
  43. Curtiss C, Cohn JN, Vrobel T, Franciosa JA (1978) Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 58:763–770PubMedGoogle Scholar
  44. Dahlström U, Karlberg BE (1982) Short and long-term effects of treatment with low dose captopril in patients with severe congestive heart failure. Br J Clin Pharmacol [Suppl2] 14:231S–235SGoogle Scholar
  45. Davis R, Ribner HS, Keung E, Sonnenblick EH, LeJemtel TH (1979) Effect of captopril in heart failure. N Engl J Med 301:117–121PubMedGoogle Scholar
  46. deJonge A, Wilffert P, Kalkmann HO, Thoolen MJMC, vanMeel JCA, Timmermans PBMWM, Zwieten PA van (1982) Effect of captopril on the regulation of noradrena-line release in the heart and vascular smooth muscle of the pitched rat. Br J Pharmacol 75:134Google Scholar
  47. Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs L, Hollenberg NK (1980) Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 302:1373–1379PubMedGoogle Scholar
  48. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH (1981) Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63:645–651PubMedGoogle Scholar
  49. Elkayam V, LeJemtel TH, Mathur M, Ribner HS, Frishman WH, Strom J, Sonnenblick EH (1979) Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol 44:540–545PubMedGoogle Scholar
  50. Faxon DP, Creager MA, Halperin JL (1982) Regional circulatory response to converting-enzyme inhibition in congestive heart failure. Br J Clin Pharmacol [Suppl 2] 14:179S–186SGoogle Scholar
  51. Feldmann AC, Ball AM, Winchester MA, Jaillon P, Kates RE, Harrison DC (1981) Beneficial hemodynamic response to chronic prazosin therapy in congestive heart failure. Am Heart J 101:534–540Google Scholar
  52. Ferguson RK, Turini G A, Brunner HR, Gavras H, McKinstry DN (1977) A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet 1:775–778PubMedGoogle Scholar
  53. Fouad FM, Tarazi RC, Bravo EL, Hart NJ, Castle LW, Salcedo EE (1982) Long-term control of congestive heart failure with captopril. Am J Cardiol 49:1489–1496PubMedGoogle Scholar
  54. Franciosa JA, Cohn JN (1980) Sustained hemodynamic effects without tolerance during long-term isosorbide dinitrate treatment of chronic left ventricular failure. Am J Cardiol 45:648–654PubMedGoogle Scholar
  55. Franciosa JA, Pierpont G, Cohn JN (1977) Hemodynamic improvement after oral hydra-lazine in left ventricular failure. A comparison with nitroprusside infusion in 16 patients. Ann Intern Med 86:388–393PubMedGoogle Scholar
  56. Franciosa JA, Nordstrom LA, Cohn JN (1978) Nitrate therapy for congestive heart failure. JAMA 240:443–446PubMedGoogle Scholar
  57. Franciosa JA, Weber KT, Kinasewitz GT, West JW, Cohn JN (1980) Long-term hydrala-zine versus placebo therapy of chronic heart failure. Circulation [Suppl III] 62:994 (Abstr)Google Scholar
  58. Goldberg S, Mann T, Grossmann W (1978) Nitrate therapy of heart failure in valvular heart disease. Importance of resting level of peripheral vascular resistance in determining cardiac output response. Am J Med 65:161–166PubMedGoogle Scholar
  59. Graham RM, Thorneil IR, Gain JM, Bagnoli C, Oates HF, Stokes GS (1976) Prazosin: the first-dose phenomenon. Br Med J 2:1293–1294PubMedGoogle Scholar
  60. Greenberg BH, Massie BM, Brundage BH, Botvinick EH, Parmley WW, Chatterjee K (1978) Beneficial effects of hydralazine in severe mitral regurgitation. Circulation 58:273–279PubMedGoogle Scholar
  61. Greenberg BH, DeMots H, Murphy E, Rahimtoola SH (1980) Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency. Circulation 62:49–55PubMedGoogle Scholar
  62. Greenberg BH, DeMots H, Murphy E, Rahimtoola SH (1982) Arterial dilators in mitral regurgitation : effects on rest and exercise hemodynamics and long-term clinical follow-up. Circulation 65:181–187PubMedGoogle Scholar
  63. Hecht HS, Karahalios SE, Schnugg SJ, Ormiston JA, Hopkins JM, Rose JG, Singh BN (1982) Improvement in supine bicycle exercise performance in refractory congestive heart failure after isosorbide dinitrate : Radionuclide and hemodynamic evaluation of acute effects. Am J Cardiol 49:133–140PubMedGoogle Scholar
  64. Heel RC, Broyden RN, Speight TM, Avery GS (1980) Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20:409–452PubMedGoogle Scholar
  65. Hepp A, Schick KD, Larbig D, Haasis R, Liebau G, Riegger G, Kochsiek K (1980) Uneinheitliche Wirkung von Prazosin auf die Linksherzinsuffizienz im akuten Versuch. Dtsch Med Wochenschr 105:1647–1650PubMedGoogle Scholar
  66. Himmler FC, Wirtzfeld A, Klein G, Volger E, Schmidt G (1980) Hämodynamische Wirkung von Prazosin bei Patienten mit schwerer Herzinsuffizienz. Herz/Kreisl 12:317–322Google Scholar
  67. Hobbs DC, Twomey TM, Palmer RF (1978) Pharmacokinetics of prazoin in man. J Clin Pharmacol 18:402–406PubMedGoogle Scholar
  68. Judson WE, Hollander W, Wilkins RW (1956) The effects of intravenous Apresoline® (hydralazine) and cardiovascular and renal functions in patients with and without congestive heart failure. Circulation 13:664–674PubMedGoogle Scholar
  69. Kersting F, Samosny G, Kasper W, Meinertz T, Gilfrich H-J, Just H (1980) Clinical pharmacology of prazosin and phentolamine in patients with heart failure. J Cardiovasc Pharmacol [Suppl] 2:S373Google Scholar
  70. Khatri I, Vemura N, Notargiacomo A, Freis ED (1977) Direct and reflex cardiostimulating effects of hydralazine. Am J Cardiol 40:38–42Google Scholar
  71. Kilcoyne MM, Schmidt DH, Cannon PJ (1973) Intrarenal blood flow in congestive heart failure. Circulation 47:786–797PubMedGoogle Scholar
  72. Kirchertz EJ, Scheler F (1982) Neubewertung Captopril-assoziierter Nebenwirkungen. Dtsch Med Wochenschr 107:345–347PubMedGoogle Scholar
  73. Kment A, Klepzig M, Büll U, Strauer BE (1980) Koronare Hämodynamik und myokardialer Sauerstoffverbrauch unter Dihydralazininfusionen. Verh Dtsch Ges Inn Med 86:633–639Google Scholar
  74. Kment A (1981) Vasodilatatoren bei normotensiver und hypertensiver Herzinsuffizienz. Internistische Welt 4:497–504Google Scholar
  75. Koch-Weser J (1976) Drug therapy: hydralazine. N Engl J Med 295:320–323PubMedGoogle Scholar
  76. Kramer B, Topic N, Massie B (1982) Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure. Br J Clin Pharmacol [Suppl 2] 14:143S–151SGoogle Scholar
  77. Kuck KH, Hanrath P, Zehnke A, Mathey D, Bleifeld W (1980a) Prazosin — Langzeitbehandlung der schweren chronischen Herzinsuffizenz, Wirkung auf die Ruhe- und Belastungshämodynamik. Dtsch Med Wochenschr 105:1384–1388Google Scholar
  78. Kuck KH, Hanrath P, Zehnke A, Mathey D, Bleifeld W (1980b) Hemodynamic effects of long-term prazosin therapy in patients with congestive heart failure. J Cardiovasc Pharmacol [Suppl 3] 2:S427–S441Google Scholar
  79. Kuhn H, Bock H, Lösse B (1981) Wirkung einer chronischen Verabreichung von Prazosin mit kongestiver Kardiomyopathie. Z Kardiol 70:501–507PubMedGoogle Scholar
  80. Lehmann M, Keul J (1982) Katecholamine in der Funktionsdiagnostik des Herzens. Die Beziehung der Plasmakatecholamine zur Herzgröße, Förderleistung und zum Füllungsdruck des insuffizienten Herzens. Herz/Kreisl 14:142–148Google Scholar
  81. LeJemtel TH, Keung E, Frishman WH, Ribner HS, Sonnenblick EH (1982) Hemodynamic effects of captopril in patients with severe chronic heart failure. Am J Cardiol 49:1484–1488PubMedGoogle Scholar
  82. Leier CV, Desch CE, Magorien RD, Triffon DW, Unverferth DV, Boudoulas H, Lewis RP (1980) Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure. Am J Cardiol 46:1039–1044PubMedGoogle Scholar
  83. Leier CV, Magorien RD, Desch CE, Thompson MJ, Unverferth DV (1981) Hydralazine and isosorbide dinitrate : comparative central and regional hemodynamic effects when administered alone or in combination. Circulation 63:102–109PubMedGoogle Scholar
  84. Lemke R, Trompler A, Kaltenbach M, Bussmann W-D (1981) Controlled study of longterm prazosin in refractory heart failure. Eur Heart J 2:211–216PubMedGoogle Scholar
  85. Lemke R, Lippok R, Kaltenbach M, Bussmann W-D (1978) Orale Langzeitbehandlung der chronischen Linksherzinsuffizienz mit Isosorbiddinitrat und Phentolamin. Z Kardiol [Suppl 5] 167:16 (Abstr)Google Scholar
  86. Lemke R, Lippok R, Kaltenbach M, Bussmann W-D (1979a) Orale Langzeittherapie der therapierefraktären chronischen Herzinsuffizienz mit Isosorbiddinitrat im Vergleich zu Phentolamin. Z Kardiol 68:82–88Google Scholar
  87. Lemke R, Trompler A, Kaltenbach M, Bussmann W-D (1979b) Wirkung von Prazosin bei der therapierefraktären chronischen Herzinsuffizienz. Dtsch Med Wochenschr 104:1769–1773Google Scholar
  88. Levine TB, Curlyle PF, Gross KA, Franciosa JA, Cohn JN (1979) Hemodynamic and clinical response to captopril in congestive heart failure. Circulation 59/60:11–39Google Scholar
  89. Levine TB, Franciosa JA, Cohn JN (1980) Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation 62:35–41PubMedGoogle Scholar
  90. Liebau G (1982) Captopril bei Herzinsuffizienz. Klin Wochenschr 60:107–113PubMedGoogle Scholar
  91. Liebau G, Riegger AJG, Schanzenbächer P, Steilner H, Oehrlein S (1982) Captopril in congestive heart failure. Br J Clin Pharmacol [Suppl 2] 14:193S–199SGoogle Scholar
  92. Machow P, Vatner SF (1982) Effects of prazosin on coronary and left ventricular dynamics in conscious dogs. Circulation 65:1186–1192Google Scholar
  93. Magorien RD, Brown GP, Unverferth DV, Nelson S, Boudoulas H, Bambach D, Leier CV (1982) Effects of hydralazine on coronary blood flow and myocardial energetics in congestive heart failure. Circulation 65:528–533PubMedGoogle Scholar
  94. Man In’t Veld AJ, Wenting GJ, Schalekamp MADH (1979) Does captopril lower blood pressure in anephric patients? Br Med J 1110Google Scholar
  95. Mason DT, Hermanovich J, Evenson M, Awan NA (1980) Oral captopril in ambulatory management of severe congestive heart failure : sustained beneficial effects on ventricular function with 6 months therapy shown by cardiac catheterization, nuclear scinitgraphy, echography, treadmill exercise and symptomatology. Am J Cardiol 45:411 (Abstr)Google Scholar
  96. Massie B, Chatterjee K, Werner J (1977a) Hemodynamic advantage of combined administration of hydralazine orally and nitrate nonparenterally in the vasodilator therapy of chronic heart failure. Am J Cardiol 40:794–801Google Scholar
  97. Massie B, Chatterjee K, Werner J, Greenberg B, Hart R, Parmley WW (1977b) Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. Am J Cardiol 40:794–801Google Scholar
  98. Massie B, Ports T, Chatterjee K, Parmley WW, Ostland J, O’Young J, Haughom F (1981a) Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation 63:269–278Google Scholar
  99. Massie B, Kramer B, Haughom F (1981b) Postural hypotension and tachycardia during hydralazine-isosorbide dinitrate therapy for chronic heart failure. Circulation 63:658–664Google Scholar
  100. Massie BM, Kramer B, Haughom F (1981c) Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance. Circulation 64:1218–1226Google Scholar
  101. Massie B, Kramer BL, Topic N, Henderson SG (1982) Hemodynamic and radionuclide effects of acute captopril therapy for heart failure changes in left and right ventricular volumes and function at rest and during exercise. Circulation 65:1374–1381PubMedGoogle Scholar
  102. Mathey DG (1983) The use of hydralazine for chronic cardiac failure: results and unanswered questions. In: Just H, Bussmann W-D (eds) Vasodilators in chronic hart failure. Springer, Berlin Heidelberg New York, pp 131–138Google Scholar
  103. Mathey D, Hanrath P, Polster J, Witte G, Montz R, Bleifeld W (1980) Acute and chronic effects of oral hydralazine on left ventricular pump function and renal hemodynamics in chronic left heart failure. Eur Heart J 1:25–29PubMedGoogle Scholar
  104. McMahon FG (1978) Management of essential hypertension. Futura, Mount Kisco, New York, chap VIII, p 233Google Scholar
  105. Meinertz T (1983) Pharmacokinetics of nitrates. In: Just H, Bussmann W-D (eds) Vasodilators in chronic heart failure. Springer, Berlin Heidelberg New York, pp 82–83Google Scholar
  106. Metha J, Miles D, Iacona M, Conti CR (1981) Long-term maintenace therapy with prazosin in congestive heart failure. Clin Cardiol 4:139–145Google Scholar
  107. Miller JA, Jonston CI (1979) Sequential changes in circulating levels of angiotensin I and II, renin, and bradykinin after captopril. Med J Aust [Suppl] 2:15–17Google Scholar
  108. Morrow JD, Schroeder HA, Perry HM Jr (1953) Studies in the control of hypertension by hyphex. II. Toxic reaction and side effects. Circulation 8:829PubMedGoogle Scholar
  109. Moulds RFW, Jauernig RA (1977) Mechanism of prazosin collapse. Lancet I:200–201Google Scholar
  110. Murthy VS, Waldron TL, Goldberg ME (1978) The mechanism of bradykinin potentiation after inhibition of angiotensin-converting-enzyme by SQ 14,255 in conscious rabbits. Circ Res [Suppl I] 43:40–45Google Scholar
  111. Nicholls MG, Ikram H, Espiner EA, Maslowski AH, Scandrett MS, Penman T (1982) Hemodynamic and hormonal responses during captopril therapy for heart failure. Acute chronic and withdrawal studies. Am J Cardiol 49:1497–1501PubMedGoogle Scholar
  112. Ondetti MA, Williams NJ, Sabo EF, Luscec J, Weaver ER, Kocy O (1971) Angiotensinconverting enzyme inhibitors from the venom of Bothrobs jararaca. Isolation, elucidation of structure and synthesis. Biochemistry 10:4033PubMedGoogle Scholar
  113. Ondetti MA, Rubin B, Cushman DW (1977) Design of specific inhibitors of angiotensinconverting enzyme: new class of orally active antihypertensive agents. Science 196:441–444PubMedGoogle Scholar
  114. Packer M, Meller J, Gorlin R, Herman MW (1979) Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation 59:531–539PubMedGoogle Scholar
  115. Packer M, Meller J, Medina N, Gorlin R, Herman MV (1980) Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. N Engl J Med 303:250–254PubMedGoogle Scholar
  116. Pals DT, Masucci FD, Sipos F, Denning GS Jr (1971) A specific competitive antagonist of the vascular action of angiotensin II. Circ Res 29:664–672PubMedGoogle Scholar
  117. Pierpont GL, Francis GS, Cohn JN (1981) Effect of captopril on renal function in patients with congestive heart failure. Br Heart J 46:522–527PubMedGoogle Scholar
  118. Rabinowitz B, Tamari I, Elazar E, Neufeld HN (1982) Intravenous isosorbide dinitrate in patients with refractory pump failure and acute myocardial infarction. Circulation 65:771–778PubMedGoogle Scholar
  119. Reifart N, Bunge T, Kaltenbach M, Bussmann W-D (1982) Akute Wirkung und Langzeittherapie mit Dihydralazin in Ruhe und unter Belastung bei schwerer chronischer Herzinsuffizienz. Z Kardiol 71:75–81PubMedGoogle Scholar
  120. Reifart M, Schmidt-Moritz AD, Nadj M, Kaltenbach M, Bussmann W-D (1983) Langzeittherapie mit Prazosin bei chronischer Herzinsuffizienz. Randomisierte Doppelblind-Studie. Z Kardiol [Suppl 1] 72:84 (Abstr)Google Scholar
  121. Ricci S, Zaniol P, Teglio V, Baraldi P, Mattioli G (1982) Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure. Br J Clin Pharmacol [Suppl 2] 14:209S–215SGoogle Scholar
  122. Rouleau J-L, Chatterjee K, Benge W, Parmley WW, Hiramatsu B (1982) Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosine in chronic ischemic heart failure: A comparative study. Circulation 65:671–678PubMedGoogle Scholar
  123. Rubin SA, Chatterjee K, Gelberg HJ, Ports TA, Brundage BH, Parmley WW (1979) Paradox of improved exercise but not resting hemodynamic with short-term prazosin in chronic heart failure. Am J Cardiol 43:810–815PubMedGoogle Scholar
  124. Scheler F, Krohne HJ (1983) Typische Risiken bei der Behandlung der arteriellen Hypertonie. Internist (im Druck)Google Scholar
  125. Sharpe DN, Coxon RJ (1982) Clinical and hemodynamic effects of low dose captopril in severe chronic heart failure. Br J Clin Pharmacol [Suppl 2] 14:161S–167SGoogle Scholar
  126. Sharpe DN, Douglas JE, Coxon RJ, Long B (1980) Low-dose captopril in chronic heart failure: Acute hemodynamic effects and long-term treatment. Lancet II:1154–1157Google Scholar
  127. Schneider W, Stahl B, Kaltenbach M, Bussmann W-D (1982) Dosis-Wirkungsbeziehung bei der Behandlung der koronaren Herzkrankheit mit Isosorbiddinitrat. Dtsch Med Wochenschr 107:771–776PubMedGoogle Scholar
  128. Schneider W, Wietschoreck A, Bussmann W-D, Kaltenbach M (1983) Untersuchungen zur Langzeitwirkung hoher Nitratdosen bei Patienten mit koronarer Herzkrankheit. Z Kardiol [Suppl 1] 72:99 (Abstr)Google Scholar
  129. Starke K (1977) Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol 77:1–124PubMedGoogle Scholar
  130. Starke K (1981) Prazosin — Pharmakologie und Wirkmechanismus. Therapeut Umschau 38:24–27Google Scholar
  131. Störger H, Hadler D, Reifart N, Kaltenbach M, Bussmann W-D (1984) Langzeittherapie mit Captopril bei schwerer chronischer Herzinsuffizienz. Z Kardiol (Suppl) (im Druck)Google Scholar
  132. Taylor JA, Twomey TM, Schach von Wittenau M (1977) The metabolic fate of prazosin. Xenobiotica 7:357–364PubMedGoogle Scholar
  133. Turini GA, Brunner HR, Ferguson RK, Rivier JL, Gavras H (1978) Congestive heart failure in normotensive man. Hemodynamics, renin, and angiotensin II blockade. Br Heart J 40:1134–1142PubMedGoogle Scholar
  134. Turini GA, Brunner HR, Gribic M, Waeber B, Gavras H (1979) Improvement of chroniccongestive heart failure by oral captopril. Lancet 1:1213–1215PubMedGoogle Scholar
  135. Turini GA, Brunner HR (1983) The renin-angiotensin-aldosteron system in congestive heart failure. In: Just H, Bussmann W-D (eds) Vasodilators in chronic heart failure. Springer, Berlin Heidelberg New York, pp 47–57Google Scholar
  136. Van Zwieten PA, Van Meel JCA, DeJonge A, Kalkman AO, Timmermanns PBMWM (1982) Zur Pharmakologie vasodilatorisch wirksamer Pharmaka; neuere Entwicklungen. Verh Dtsch Ges Kreislaufforsch 48:78–86Google Scholar
  137. Vidt DG, Bravo EL, Fouad FM (1982) Captopril. In: Koch-Weser J (ed) Drug therapy. N Engl J Med 306:214–219PubMedGoogle Scholar
  138. Walsh WF, Greenberg BH (1981) Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation 64:499–505PubMedGoogle Scholar
  139. Willerson JT (1982) What is wrong with the failing heart? N Engl J Med 307:243–245PubMedGoogle Scholar
  140. Wilson JR, Untereker W, Hirshfeld J (1981) Effects of isosorbide dinitrate and hydralazine on regional metabolic responses to arm exercise in patients with heart failure. Am J Cardiol 48:934–938PubMedGoogle Scholar
  141. Wirtzfeld A, Klein G, Himmler FC, Schmidt G, Kutschera I, Sauer E (1980) Oral wirksame Vasodilatatoren bei der chronischen therapieresistenten Herzinsuffizienz. Wirkungsvergleich von Isosorbiddinitrat, Prazosin und Dihydralazin. Dtsch Med Wochenschr 105:1379–1383PubMedGoogle Scholar
  142. Zelis R, Flaim SF (1983) Vasoconstrictor mechanisms and the effect of nitrates. In: Just H, Bussmann W-D (eds) Vasodilators in chronic heart failure. Springer, Berlin Heidelberg New York, pp 1–13Google Scholar
  143. Zelis R, Flaim SF (in Vorbereitung) Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc DisGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • W.-D. Bussmann

There are no affiliations available

Personalised recommendations